**Original Article**

**MiR-18a-5p acts as a novel serum biomarker for venous malformation and promotes angiogenesis by regulating the thrombospondin-1/P53 signaling axis**

Liming Zhang¹, Deming Wang¹*, Zhenfeng Wang¹, Xiao Li², Weiya Xia², Yifeng Han¹, Lixin Su¹, Xindong Fan¹

¹Department of Interventional Therapy, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China; ²Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Texas 77030, USA. *Equal contributors.

Received June 10, 2021; Accepted August 16, 2021; Epub October 15, 2021; Published October 30, 2021

**Abstract:** Venous malformation (VM) is a kind of congenital vascular anomaly with high recurrence, and screening for VM lacks an efficient, inexpensive and noninvasive approach now. Serum miRNAs with stable structures are expected to become new postoperative and postablative monitoring biomarkers. Thus, we identified a prognostic serum miR-18a-5p and validated its function in VM. Notably, higher expression level of miR-18a-5p was detected in VM patients than in healthy individuals. We found that miR-18a-5p plays a promotive role in human umbilical vein endothelial cells in vitro. In addition, immunohistochemistry (IHC) results showed a distinct increase of vessels in miR-18a-5p mimics group and a decrease of vessels in inhibitors group compared to the control group in a murine VM model. Furthermore, thrombospondin-1 (TSP1), a potential miR-18a-5p-binding protein, was identified via RNA-seq, luciferase reporter and RNA immunoprecipitation (RIP) assays. Moreover, miR-18a-5p regulated the activation of P53 signaling pathway constituents and consequently led to the regulation of proliferation, migration, invasion and angiogenesis. These results provide a strong theoretical basis for further investigations into pathological mechanism of VM and may provide novel and noninvasive biomarker for VM diagnosis and monitoring.

**Keywords:** Serum, miR-18a-5p, biomarker, venous malformation, thrombospondin-1, P53

**Introduction**

Venous malformation (VM) is a commonly encountered vascular malformation with an incidence of approximately 1% of the population [1, 2]. Deficits in venous network development lead to dysfunctional venous channels [3, 4]. These low-flow venous sacs develop at birth and progressively expand along with age; ultimately, these sacs infiltrate and compress normal adjacent tissues [5]. Clinically, symptoms of VM range from small blue localized varicosities to massively swollen lesions [6]. VM may result in not only pain and coagulation abnormalities, but also some potentially life-threatening complications [7] (Figure 1A). There are several treatment techniques available, including sclerotherapy, surgery and laser ablation [8], however, there is currently no standard treatment for VM, and the outcomes of some patients are still not satisfactory, especially for those with massive lesions. Thus, efficient evaluation and screening of VM is still a medical challenge.

MicroRNAs (miRNAs) are 18 to 25 nucleotides non-coding RNAs that regulate numerous pathological processes by binding to target mRNA sequences and inhibiting translation [9, 10]. Previous studies showed that miRNAs are relatively stable in serum, which makes it possible to monitor the presence and progression of diseases via miRNA analysis [11-14]. A previous study reported that miR-145 may be involved in the sclerotherapy of VM [15] despite not having a valuable clinical function, so more researches are needed to find promising miRNAs in blood for the evaluation and management of VM. MiR-18a-5p, belonging to the miR-17-92 miRNA cluster, has been reported to participate in brain arteriovenous malformations (BAVMs) [16] and pulmonary arterial
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

miR-18a-5p/TSP1/P53 signaling regulates venous malformation

Figure 1. Serum expression of miR-18a-5p in VM patients. A. VM lesions involving the tongue, face and legs, which seriously affected the appearance and function of patients. Red arrows represent the VM lesions. B. The MRI imaging below shows extensive disordered vessels. Red arrows represent the VM lesions. C. A comparison of serum miR-18a-5p levels in VM patients and healthy controls (unpaired t test, **P<0.05). D. The diagnostic accuracy of serum miR-18a-5p for discriminating VM patients and healthy controls. E. Comparison of serum miR-18a-5p in paired pre- and post-operative samples (n = 41). **P<0.05 (paired t test). Data were obtained from three independent repeated experiments. **P<0.05; n.s.: not significant.

hypertension (PAH) [17], indicating that miR-18a-5p may contribute to the process of angiogenesis. Besides, a previous study has reported that miR-18a-5p can function as an effective index of radio-sensitivity in treating lung cancer [18]. Although miR-18a-5p has been characterized regarding its function in many diseases, its role in the pathophysiology of VM has yet to be elucidated.

In this work, we first studied serum samples from venous malformation patients and analyzed the level of angiogenic-related miR-18a-5p, which could potentially act as a serum biomarker for monitoring VM. In addition, we performed some studies to identify the potential target genes of miR-18a-5p and explored the regulatory mechanisms of miR-18a-5p function in venous malformation.

Materials and methods

Clinical samples

No patients received any therapy prior to treatment. We collected 143 serum samples from 102 participants, including 54 patients with VM and 48 healthy controls. The 54 patients were diagnosed with venous malformation by their clinical features and magnetic resonance imaging (MRI). They were recruited at the Ninth People’s Hospital between 2019 and 2020.
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

(Figure 1B). Blood and serum samples from all participants were collected and stored at -80°C. We obtained informed consent from all participants for publication of identified information/images in an online open-access publication. The performance of the study followed the guidelines of the committee and the Declaration of Helsinki. All experiments were performed in accordance with the relevant guidelines and regulations. Our study was approved by the Ethics Review Committee of the Ninth People’s Hospital at the Shanghai Jiao Tong University School of Medicine.

Cell culture and infection

Human umbilical vein endothelial cells (HUVECs) were ordered from ScienCell (USA). The cells underwent mycoplasma testing and short tandem repeat (STR) analyses. Cells were cultured with MEM-α medium (Gibco, USA), including 10% fetal bovine serum (FBS) and 100 mg/ml streptomycin (Gibco, USA) and 1% penicillin. Cells were incubated at 37°C in a humidified atmosphere consisting of 5% CO₂, siTSP1, NC siRNA, TSP1 overexpression (OE) vector, NC OE vector, miR-18a-5p mimics, NC mimics, miR-18a-5p inhibitors, NC inhibitors, miR-18a-5p overexpressing (OE)-lentivirus and miR-18a-5p knockdown (KD)-lentivirus were synthesized by Genome Co. (Shanghai, China). In addition, HUVECs were screened by puromycin after lentivirus infection.

Immunohistochemistry (IHC)

IHC was performed on paraformaldehyde-fixed paraffin-embedded sections with antibodies targeting CD31, P53, bax, bcl-2 (Cell Signaling Technology) and TSP1 (Proteintech Group). Visualization was conducted via the streptavidin-peroxidase conjugation method.

Bioinformatic prediction of miR-18a-5p targets

Common genome-wide targets of miR-18a-5p were explored by using online website starBase (http://starbase.sysu.edu.cn/).

Luciferase reporter assay

We transfected pmirGLO, pmirGLO-NC-wt, pmirGLO-TSP1-wt or pmirGLO-TSP1-mut into miR-18a-5p-overexpressing HUVECs by using Lipofectamine 2000 reagent (Invitrogen, USA). The specific experimental steps were described in our previous published articles [19]. The luciferase activity was detected by Dual-Luciferase System (Promega, USA).

HE staining

We fixed matrigel nodules from animals of different group in 4% paraformaldehyde, and after 24 h, we used a gradient series of alcohol for dehydration. The details of the HE assays were described in our previous article [19]. At last, the sections were sequentially dehydrated with a gradient and fluorescence imaging was used to find the potential changes of blood vessels.

Western blotting (WB)

WB was done as described in our previous article [19]. Antibodies (1:1000) specific for TSP1, bax, P53, bcl-2, and GAPDH were bought from Cell Signaling Technology (Boston, MA, USA). Anti-p-TIE2 antibody was purchased from Affinity Biosciences (Cat# AF2424) (1:1000). All original uncropped gels of Western blot assay were shown in Supplementary Figure 1.

Statistical analysis

Data are expressed as the mean ± SD and comparisons between two groups were performed using an independent sample t-test. Data among multiple groups were compared by one-way analysis of variance (ANOVA). Statistical analyses were performed by SPSS 20.0 (SPSS, Chicago, IL, USA) and plotting and graphing were performed by GraphPad Prism 9.0 (GraphPad Software, San Diego, CA, USA). P value <0.05 was considered as statistically significant.

Supplementary methods

RNA extraction and quantitative real-time polymerase chain reaction, cell proliferation assay, transwell assay, wound healing assay, in vitro tube formation assay, RNA immunoprecipitation and establishment of an animal model of VM are described in Supplementary File 1.

Results

Serum level of miR-18a-5p in VM patients

We first conducted a comprehensive comparative analysis of serum miR-18a-5p level between 54 VM patients and 48 healthy donors. Serum expression of miR-18a-5p was dramatically higher in VM patients than in
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

healthy group (Figure 1C). Then, we performed ROC analyses to evaluate the accuracy of miR-18a-5p for predicting VM. We found that serum miR-18a-5p can well discriminate patients with VM and healthy group, and the AUC value is 0.8494 (sensitivity = 90.91%, specificity = 72.92%) (Figure 1D). In addition, we obtained pre- and post-operative serum with 41 successfully managed VM patients, and found that serum miR-18a-5p expressions of these patients were significantly downregulated after treatment (Figure 1E). These results indicated that miR-18a-5p has a potential to be a novel serum biomarker for VM screening. In addition, we evaluated the correlations between patients’ clinical characteristics and miR-18a-5p expression, all data are summarized in Table 1. Sex, age and maximum length of VMs were highly associated with serum level of miR-18a-5p. Female, age >18 and bigger VMs corresponded to higher serum miR-18a-5p level.

MiR-18a-5p promoted cell proliferation, invasion, migration and angiogenesis of HUVECs in vitro and in vivo

To explore biological function of miR-18a-5p in VM, mimics and inhibitors were separately transfected into HUVECs, and the transfection efficiency was validated via qRT-PCR (Figure 2A). We then applied CCK-8 to check the effect of miR-18a-5p on HUVEC proliferation and observed that increased miR-18a-5p contributed to the proliferation of HUVEC, while decreased miR-18a-5p attenuated HUVEC proliferation (Figure 2B). Then wound healing and transwell assays were used to examine cell invasion and migration. As shown in Figure 2C, 2E and 2F, miR-18a-5p mimics enhanced HUVEC invasion and migration, but these activities were suppressed by miR-18a-5p inhibitors. Besides, tube formation assay (an in vitro measure of angiogenesis) showed that the tube-forming ability of HUVECs was enhanced with miR-18a-5p mimics and suppressed with miR-18a-5p inhibitors (Figure 2D, 2F).

Venous malformation mouse model was constructed with previous study results [20] (Figure 2G). First, we constructed the lentivirus owning TIE2-WT-GFP or TIE2-L914F mutant-GFP, then we infected HUVECs with lentivirus. After infecting, we used WB to check the transfection efficiency (Figure 2H). The results showed that the level of phosphorylated TIE2 in HUVECs infected with TIE2-L914F mutant was higher than that of TIE2-WT group. Then, 5x10^6 HUVECs infecting lentivirus were inoculated into one side of mice in an equal volume of Matrigel subcutaneously, and the masses were resected 2 weeks after inoculation (Figure 2I). The TIE2-L914F mutation group showed masses with more vessel-like formations, and HE staining revealed that the HUVECs infecting TIE2-L914F mutation could cause more vessels (Figure 2J).

To validate whether miR-18a-5p has an effect on angiogenesis in vivo, TIE2-L914F mutant HUVECs were transfected with miR-18a-5p inhibitors, mimics or vehicle for 72 h. Three groups of cells with different treatments were seeded into mice as previously described

Table 1. Clinicopathological features correlated with serum miR-18a-5p expression in VM patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number of cases (%)</th>
<th>Expression of serum miR-18a-5p</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>High (%)</td>
<td>Low (%)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>26 (48.1)</td>
<td>9 (34.6)</td>
<td>17 (65.4)</td>
</tr>
<tr>
<td>Female</td>
<td>28 (51.9)</td>
<td>18 (64.3)</td>
<td>10 (35.7)</td>
</tr>
<tr>
<td>Ages, years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤18</td>
<td>27 (50.0)</td>
<td>9 (33.3)</td>
<td>18 (66.7)</td>
</tr>
<tr>
<td>&gt;18</td>
<td>27 (50.0)</td>
<td>18 (66.7)</td>
<td>9 (33.3)</td>
</tr>
<tr>
<td>Max length, cm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2 cm</td>
<td>23 (42.6)</td>
<td>3 (13.0)</td>
<td>20 (87.0)</td>
</tr>
<tr>
<td>&gt;2 cm, ≤4 cm</td>
<td>22 (40.7)</td>
<td>17 (77.3)</td>
<td>5 (22.7)</td>
</tr>
<tr>
<td>&gt;4 cm</td>
<td>9 (16.7)</td>
<td>8 (88.9)</td>
<td>1 (11.1)</td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lips</td>
<td>11 (20.4)</td>
<td>6 (54.5)</td>
<td>5 (45.5)</td>
</tr>
<tr>
<td>Cheek</td>
<td>6 (11.1)</td>
<td>3 (50.0)</td>
<td>3 (50.0)</td>
</tr>
<tr>
<td>Orbital</td>
<td>3 (5.6)</td>
<td>2 (66.7)</td>
<td>1 (33.3)</td>
</tr>
<tr>
<td>Tongue</td>
<td>22 (40.7)</td>
<td>10 (45.5)</td>
<td>12 (54.5)</td>
</tr>
<tr>
<td>Limb</td>
<td>4 (7.4)</td>
<td>2 (50.0)</td>
<td>2 (50.0)</td>
</tr>
<tr>
<td>Body</td>
<td>2 (3.7)</td>
<td>1 (50.0)</td>
<td>1 (50.0)</td>
</tr>
<tr>
<td>Other</td>
<td>6 (11.1)</td>
<td>3 (50.0)</td>
<td>3 (50.0)</td>
</tr>
</tbody>
</table>

Abbreviations: VM, venous malformation; Max length, maximum length of VM according to the MRI results; **P<0.05.
miR-18a-5p/TSP1/P53 signaling regulates venous malformation
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

Figure 2. MiR-18a-5p promoted cell proliferation, invasion, migration and angiogenesis of HUVECs in vitro and in vivo. (A) MiR-18a-5p expression was measured via qRT-PCR in HUVECs transfected with plasmids for 48 h. (B) Cell viability was measured by CCK-8 assay in HUVECs transfected with miR-18a-5p inhibitors, miR-18a-5p mimics or corresponding NCs. (C-F) Results of transwell (C, up F), tube formation (D, middle F), and wound healing assays (E, down F) in HUVECs transfected with miR-18a-5p inhibitors, miR-18a-5p mimics or corresponding NCs. (G) Schematic diagram: establishment and treatment of the VM mouse model. (H) The phosphorylated TIE-2 level was detected by Western blot assay. (I) The lesions were harvested 2 weeks after inoculation. (J) H&E and CD31 staining of the lesions. (K) Lesions and H&E staining at 18 days after inoculation of VM model mice subjected to different treatments. (L) Growth curve of the lesion area shows the speed of VM mass growth. (M) The weight of masses excised from mice in the ectopic expression and vector groups were measured and analyzed. The relative expression fold changes in mRNA expression were calculated by the $2^{ΔΔCt}$ method. Data were obtained from three independent repeated experiments. **P<0.05; n.s.: not significant.
We measured the masses every 3 days and harvested them 18 days after treatment. We observed that miR-18a-5p inhibitors group showed the least vessel formation, and the extent of vessel formation was medium in the vehicle group, whereas miR-18a-5p mimics group showed the most vessels by H&E staining (Figure 2K). Compared to the vehicle group, the miR-18a-5p inhibitors group presented smaller lesion areas and a larger total weight of the masses, whereas miR-18a-5p mimics group showed the most vessels by H&E staining (Figure 2L, 2M). Thus, we hypothesized that miR-18a-5p plays a promotive role in VM progression in vivo and in vitro.

Identification of miR-18a-5p target genes in HUVECs

To study the regulatory mechanisms of miR-18a-5p in HUVECs, we constructed stable miR-18a-5p-overexpressing (OE) and miR-18a-5p-knockdown (KD) HUVECs by infecting the cells with lentivirus (Figure 3A). Then, we used RNA-seq to discriminate the differentially expressed genes between the overexpressing group, control group and knockdown group. We used a Venn diagram to show all differentially expressed genes (Figure 3B and Supplementary Figure 2A-D). And in Figure 3C, 7 miR-18a-5p-regulated genes with significant fold changes were chosen to be validated in HUVECs. qRT-PCR was conducted to evaluate the level of indicated genes in HUVECs transfected with either lentivirus-miR-18a-5p OE or KD. Results showed that thrombospondin-1 (TSP1) exhibited the largest increase compared with the other 6 genes; thus, we chose TSP1 for further study (Figure 3C). We then did Western blot to validate the expression of TSP1 in miR-18a-5p OE or KD groups (Figure 3D). It is well known that miRNAs mostly bind to the 3’ UTR region of target mRNAs [21]. To determine potential binding sites that interact with miR-18a-5p, we used starBase 3.0, an online public resource that identifies target mRNAs of miRNAs, to identify the binding sites. To verify whether the biological functions of miR-18a-5p are dependent on the binding to the 3’ UTR of TSP1, we constructed a luciferase reporter vector containing the TSP1 3’ UTR with wild-type or mutated miR-18a-5p binding site (Figure 3E). And results showed that, luciferase activity of the TSP1 3’ UTR wild-type reporter was decreased when HUVECs were transfected with the miR-18a-5p mimics but has no significant difference when transfected with scramble control or when miR-18a-5p mimics were co-transfected with the mutant TSP1 3’ UTR reporter (Figure 3F).

We further analyzed whether miR-18a-5p form the RISC complex with TSP1 by conducting an RIP assay. In brief, FLAG-tagged AGO2 (Argonaute 2) was overexpressed in HUVECs. And then endogenously bound RNAs were pulled down and purified, followed by qRT-PCR analysis. We postulated that if miR-18a-5p can bind TSP1 mRNA, miR-18a-5p overexpression could lead to a raise of TSP1 mRNAs with AGO2 (Figure 3G). Lastly, an enrichment of TSP1 mRNA with AGO2 in cells overexpressing miR-18a-5p was validated (Figure 3H). All these data indicated that miR-18a-5p guides AGO2 proteins to TSP1 mRNA. Thus, we concluded that miR-18a-5p directly regulates TSP1 gene in HUVECs.

TSP1 restored the function of miR-18a-5p in HUVECs

To explore the mechanism of TSP1 in HUVECs, we first transfected TSP1 siRNA and a vector into HUVECs, and then checked their efficiency via qRT-PCR and Western blot assays (Figure 4A, 4B). We then explore the role of TSP1 in HUVECs by performing CCK-8, wound healing, tube formation and transwell assays (Figure 4C-G and Supplementary Figures 2B, 3A). All the assay results showed that TSP1 can inhibit proliferation, invasion, angiogenesis and migration in HUVECs. Next, we performed rescue experiments by downregulating TSP1 expression in miR-18a-5p KD HUVECs and upregulating TSP1 expression in miR-18a-5p OE HUVECs. We found that TSP1 can restore the promotive role of miR-18a-5p in HUVECs (Figure 4H-K and Supplementary Figure 3C-E). These data further support our hypothesis that miR-18a-5p exerts its function by regulating TSP1 expression in HUVECs.

Verification of the regulatory relationship between miR-18a-5p and the P53 signaling pathway in vitro and in vivo

According to the results of GO function and KEGG pathway enrichment analyses (Figure 5A and Supplementary Figure 4A-C), P53 signaling pathway...
miR-18a-5p/TSP1/P53 signaling regulates venous malformation
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

Figure 3. Identification of miR-18a-5p target genes in HUVECs. A. Expression levels of miR-18a-5p in HUVECs transfected with lentivirus either overexpressing miR-18a-5p (OE) or miR-18a-5p knockdown (KD). B. Venn diagram and prediction legends of the target genes regulated by miR-18a-5p in HUVECs. C. Relative expression of putative target genes in HUVECs transfected with NC, miR-18a-5p OE or miR-18a-5p KD. D. Expression levels of TSP1 were measured via Western blot in HUVECs transfected with NC, miR-18a-5p OE or miR-18a-5p KD. E. Potential miR-18a-5p base pairing alignment with TSP1 (blue), as identified by starBase v3.0. A mutation in the putative binding site was also established (red). F. Luciferase activity in HUVECs co-transfected with miR-18a-5p mimics and luciferase reporters containing empty vector, TSP1-wt or TSP1-mutant transcripts. G. Scheme of the RIP assay of AGO2-FLAG pull-down and RT-qPCR analysis of endogenous mRNA enrichment upon miR-18a-5p overexpression. H. QRT-PCR analysis of endogenous TSP1 mRNA upon immunoprecipitation of AGO2-FLAG in one representative experiment of three replicates. Data were obtained from three independent repeated experiments. **P<0.05; n.s.: not significant.
miR-18a-5p/TSP1/P53 signaling regulates venous malformation
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

Figure 4. TSP1 restored the function of miR-18a-5p in HUVECs. (A, B) Expression of TSP1 in HUVECs transfected with siRNA NC, siTSP1, NC vector and TSP1 vector was examined by qRT-PCR (A) and Western blot (B). (C) The viability of HUVECs after transfection with TSP1 vector or siTSP1 was determined using CCK-8 assay. (D, E) A wound healing assay was performed with HUVECs transfected with TSP1 vector or siTSP1. (F, G) Tube formation (F) and transwell assays (G) were conducted in HUVECs with TSP1 vector or siTSP1. (H-K) Growth, invasion, migration and angogenesis of HUVECs transfected with NC, miR-18a-5p OE, miR-18a-5p KD, miR-18a-5p OE + TSP1 OE vector or miR-18a-5p KD + siTSP1 were evaluated by CCK-8 (H), wound healing (I), tube formation (J) and transwell assays (K). Data were obtained from three independent repeated experiments. **P<0.05; n.s.: not significant.

Figure 5. Verification of the regulatory relationship between miR-18a-5p and the P53 signaling pathway in vitro and in vivo. A. KEGG analysis was performed to identify pathway terms enriched in the dysregulated mRNAs in HUVECS with miR-18a-5p OE vs WT. B, C. Western blot analysis of P53 signaling-related protein levels in lysates from HUVECs transfected with NC, miR-18a-5p OE or miR-18a-5p KD. D, E. A wound healing assay was performed with HUVECs transfected with TSP1 vector or siTSP1. (F, G) Tube formation (F) and transwell assays (G) were conducted in HUVECs with TSP1 vector or siTSP1. (H-K) Growth, invasion, migration and angogenesis of HUVECs transfected with NC, miR-18a-5p OE, miR-18a-5p KD, miR-18a-5p OE + TSP1 OE vector or miR-18a-5p KD + siTSP1 were evaluated by CCK-8 (H), wound healing (I), tube formation (J) and transwell assays (K). Data were obtained from three independent repeated experiments. **P<0.05; n.s.: not significant.
pathway showed the highest enrichment score among all the affected pathways after miR-18a-5p levels changed (Figure 5A and Supplementary Figure 4A). Therefore, we postulated that miR-18a-5p and its target gene TSP1 may predominantly function through the P53 signaling pathway. Then, we assessed the protein expression of genes related to the P53 signaling pathway (P53, bax, bcl-2) after altering the expression of miR-18a-5p in HUVECs via Western blot assay (Figure 5B, 5C). We found that the expressions of P53, bax, and TSP1 were decreased while that of bcl-2 was increased in miR-18a-5p OE HUVECs; in contrast, the opposite results were observed in miR-18a-5p KD HUVECs.

To explore whether the target gene TSP1 participates in the regulation of miR-18a-5p to P53 signaling pathway, we made the same rescue experiments as for previous groups, extracted their protein and assessed these genes' expression via Western blot assay. We saw that expression of these P53 signaling pathway-related genes did show restored phenomenon when we transfected miR-18a-5p OE HUVECs with TSP1 vector or transfected miR-18a-5p KD HUVECs with siTSP1. Expression of P53, bax and bcl-2 all returned back to the original level in miR-18a-5p OE + TSP1 vector group and miR-18a-5p KD + siTSP1 group compared with the control group. (Figure 5D, 5E).

To validate previous results in vivo, we conducted an IHC assay of the cell-containing Matrigel nodules, and we analyzed the expression of TSP1, P53, bax, bcl-2 in miR-18a-5p mimics, miR-18a-5p inhibitors and control groups. We found that miR-18a-5p mimics group showed higher expression of bcl-2 and lower expression of P53, bax and TSP1, and the miR-18a-5p inhibitors group had lower expression of bcl-2 and higher expression of P53, bax and TSP1 compared with the control group (Figure 5F). Thus, we draw a conclusion that miR-18a-5p can promote VM progression by regulating the TSP1/P53 signaling pathway.

Discussion

It was reported that human serum containing miRNAs or cytokines can play important roles in various devastating diseases and infections [22-24]. There has been increasing interest in recent years in the use of human serum components as biomarkers or therapeutic targets [25, 26], particularly in the field of hematopathy. Numerous studies on the role of human serum composition in blood diseases or cancer progression have been published [27-29]. During the developmental process of human diseases, the serum composition varies profoundly. These variations include changes in the quantities and types of various miRNAs, suggesting a potential for human serum to be used for identification, monitoring and treatment of diseases [30, 31]. In our investigation, we measured the expression of serum miR-18a-5p derived from VM patients and healthy donors by quantitative real-time PCR. Our results showed that VM patients had a significantly higher serum miR-18a-5p than the healthy donors, and its expression returned to a relatively normal level when the patients' diseases were successfully controlled. All these results validate that miR-18a-5p could serve as a predictive or monitoring serum biomarker of VM.

According to the most recent studies about the function and regulation of miRNAs in other diseases, IncRNAs and circRNAs can function as competing endogenous RNAs (ceRNAs) by sponging corresponding miRNAs in various psychological and pathological processes. Lots of dysregulated ceRNAs networks have been reported and explored. Thus, another study about the differentially expressed serum exosomal circRNAs and IncRNAs has also been conducted by our team to find the possible molecular mechanism by which miR-18a-5p is up-regulated in VM patients.

Previous studies revealed that miR-18a-5p can participate in many processes of cancers [32, 33]. In addition, miR-18a-5p has also been verified to play a vital role in vascular endothelial cell proliferation, migration, invasion, and angiogenesis [34, 35]. However, the effect of miR-18a-5p on VM is still poorly understood. Our results validated that miR-18a-5p levels were higher in the serum of VM patients than healthy group. Studies showed that miR-18a-5p overexpression significantly enhanced the proliferation, migration, invasion and angiogenesis of HUVECs in vitro. Besides, downregulation of miR-18a-5p gave rise to contrary results. Previous studies have shown that miRNAs can exert their functions by affecting the expres-
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

sion of their target mRNAs [36]. Thus, to check the predictive binding and explore the potential target genes of miR-18a-5p in HUVECs, mRNA levels in miR-18a-5p knockdown and miR-18a-5p overexpression as well as in control groups were further measured by RNA-seq. Then seven genes showing the largest changes (TSP1, IGF1, CTGF, LIF, CCND2, NACC1 and MMP1) were chosen for further validation, with the TSP1 gene showing the strongest negative correlation with miR-18a-5p as checked by qRT-PCR and Western blot.

Thrombospondins (TSPs) participate in lots of physical and pathological processes, such as cell differentiation, proliferation, vascular hemeostasis and wound healing [37]. Thrombospondin-1 (TSP-1) is one of the thrombospondin family [38], and TSP-1 is mostly synthesized and secreted by platelets and endothelial cells [39]. Numerous studies have reported that TSP1 shows a wide range of biological effects, such as inhibiting angiogenesis, antitumor activity and so on [40]. Taken together, TSP1 might play an important role in the regulation of biological processes. According to our study, the level of TSP1 was directly regulated by miR-18a-5p as indicated by the results of dual-luciferase reporter and RIP assays. Besides, when miR-18a-5p expression changed in HUVECs, ectopic TSP1 expression rescued the promotive role of miR-18a-5p in HUVECs via rescue assays, indicating a latent role of TSP1 in miR-18a-5p regulatory axis in VM.

To explore the detailed mechanism of miR-18a-5p in HUVECs, we performed an RNA-seq assay. By performing KEGG analysis, we saw that P53 signaling pathway was the most important pathway regulated by miR-18a-5p. Previous studies showed that P53 can regulate gene transcription, leading to cell death, DNA injures and changes in angiogenesis [41-45]. More importantly, TSP-1 had been reported to participate in the P53 signaling in several diseases [46-48]. Thus, we decided to validate whether miR-18a-5p function by regulating the P53 signaling pathway to some degree. Remarkably, Western blot analysis of protein level showed that, overexpression of miR-18a-5p downregulated the expression of P53, bax, TSP1 and increased the expression of bcl-2 in HUVECs. By contrast, downregulating miR-18a-5p in HUVECs had the opposite effect on the expression pattern of these genes. Thus, we confirmed that miR-18a-5p can regulate TSP1 expression and further played a significant role in the P53 signaling pathway. Considering the P53 signaling pathway constituents, we also conducted the flow cytometry assay to verify the apoptosis rate of different miR-18a-5p changed groups, but we found that, there was no significant statistical difference between the three groups. Thus we postulated that, TSP1 had the angio-inhibitory signaling downstream of miR-18a-5p that might override other pro-apoptotic signaling. Besides, considering there were also lots of genes regulated by the miR-18a-5p, it may be possible that some molecules among these genes counteracted the apoptotic influence of P53 signaling pathway constituents.

Finally, to verify the function of miR-18a-5p in the vessel formation process in vivo, we established a VM mouse model, and the results suggested that compared to the control, miR-18a-5p inhibitors led to less vessel formation whereas miR-18a-5p mimics caused more vessel formation. We also found that the expression trends of TSP1 and P53 signaling-related proteins were also consistent with the in vitro expression levels in HUVECs by IHC.

To our best knowledge, our study is the first report describing the clinical significance of serum miR-18a-5p in VM. Our results suggest that miR-18a-5p can promote VM progression by suppressing TSP1 and further regulating the P53 signaling pathway (Figure 6). Therefore, serum miR-18a-5p might be a promising therapeutic target and serum biomarker for VM.

Acknowledgements

The authors would like to thank Prof. Wayne F. Yakes for teaching the technique of ethanol embolization and supporting clinical work during these years. We thank all the doctors and nurses in our apartment and the work was done with their kind help. This work was supported by National Natural Science Foundation of China (Grant No.81871458) and Clinical Research Program of Ninth People’s Hospital, Shanghai Jiaotong University, School of Medicine (Grant No. JYLJ201911 and No. JYLJ201801).

Disclosure of conflict of interest

None.
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

Figure 6. Hypothetical model describing the function of miR-18a-5p in VM. High expression of serum miR-18a-5p downregulates the expression level of TSP-1 in vascular endothelial cells, which participates in the P53 signaling pathway, resulting in VM progression.

Address correspondence to: Xindong Fan and Lixin Su, Department of Interventional Therapy, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, No. 639 Zhizhaoju Road, Shanghai 200011, China. Tel: +86-021-23271699; E-mail: fanxd1964@163.com (XDF); sulixin1975@126.com (LXS)

References

miR-18a-5p/TSP1/P53 signaling regulates venous malformation


miR-18a-5p/TSP1/P53 signaling regulates venous malformation


Supplementary File 1

Supplementary methods

RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)

Hemolysis of serum specimens was tested to remove potential contaminants. We routinely assessed the degree of overall RNA integrity to analyze RNA quality. Samples exhibiting an RNA integrity number (RIN) value greater than 7 as determined on an Agilent 2100 Bioanalyzer were included in the analysis. miRNA was isolated from serum samples with a miRNeasy Mini Kit (Qiagen). A total of 500 μl of serum was used for each experiment. For the detection of miR-18a-5p in serum samples, a synthetic C. elegans miRNA (cel-miRNA-39) was used as an internal control due to the lack of universal endogenous controls. miR-18a-5p primers were obtained from Takara Bio (sequences protected by a patent). Other primers were obtained from Sangon Biotech, and detailed primer sequence information is listed in Supplementary Table 1.

Enriched small RNAs from serum were reverse transcribed with a TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). The expression of selected miRNAs, cel-miR-39 (for normalization of serum) and U6 (for normalization of cultured cells) was tested with a TaqMan miRNA assay (Applied Biosystems).

Total RNA from cells was extracted using TRIzol reagent (Invitrogen, USA). The RNA concentration and integrity were determined by spectrophotometry and standard RNA gel electrophoresis, respectively. RNA was reverse transcribed into cDNA using a Primer-Script One-Step RT-PCR kit (TaKaRa, Dalian, China). The cDNA template was amplified by real-time PCR using a SYBR Premix DimerEraser kit (TaKaRa). Real-time PCR was performed using specific primers (Supplementary Table 1) for GAPDH, TSP1, IGF1, LIF, CCND2, NACC1 and MMP1 obtaining from Sangon Biotech. CTGF primers were obtained from Takara Bio (sequences protected by a patent). The mean cycle threshold (CT) value for each sample was analyzed using the 2^(-ΔΔCT) method. All the reactions were performed in triplicate.

Cell proliferation assay

Cell viability was measured using the Cell Counting Kit-8 (CCK-8) assay (Dojindo Laboratories, Kumamoto, Japan). After transfection for 48 hours, HUVECs were seeded into 96-well plates at a density of 1x10^3 cells per well in 100 μl of medium. Subsequently, 10 μl of CCK-8 solution with 90 μl medium was added to each well at the indicated time points. After incubation at 37°C for 90 min, the absorbance at 450 nm was measured with a plate reader. The growth curves were examined to determine the growth rates.

Transwell assay

HUVECs were seeded into the upper chamber of Transwell® cell culture inserts with an 8 μm pore size (Costar-Corning, USA) in serum-free medium. The lower chamber was filled with MEM-α supplemented with 10% FBS. After an incubation period of 48 h, the cells on the upper surface of the membrane were removed with a cotton swab, while cells in the bottom of the chamber were fixed with 70% ethanol and stained with 0.5% crystal violet solution for 30 min at room temperature. A light microscope was used to count the number of migrated cells (4 random fields per chamber).

Wound healing assay

HUVECs were plated in 6-well plates at a density of 2x10^6 cells per well. After 24 h, wounds were generated using sterilized pipette tips, and the medium was substituted with serum-free medium. Images of the plates in the same field of view were observed and captured 48 h later.

In vitro tube formation assay
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

In vitro tube formation assays were performed in 96-well plates coated with 50 μl of Matrigel Basement Membrane Matrix, Growth Factor Reduced (Corning, 354230), which was heated at 37°C for 30 min to allow gel formation. Then, 2×10⁴ HUVECs subjected to various transfections in MEM-α containing 2% FBS were seeded onto the Matrigel and incubated at 37°C for 8 h. The formation of tubes and tube-like structures was captured 8 h later using a Nikon Eclipse 80i microscope (Nikon, Japan).

RNA immunoprecipitation (RIP)

HUVECs (2×10⁶) were seeded onto 10 cm tissue culture plates and transfected with 4 μg of FLAG-AGO2 and 25 nM scr/mimic miR-18a-5p using Lipofectamine 2000 (Life). HUVECs were transfected with pBSKS (an empty plasmid) as a negative control. After transfection for 48 hours, cells were washed with ice-cold 1× PBS, scraped, and transferred to a 1.5 ml tube, followed by centrifugation at 200×g for 2 min. The cells were then resuspended in 200 μl of cold resuspension buffer (20 mM Tris (pH = 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA) containing 1 U/μl RNasin Plus (Promega) and lysed by the addition of 800 μl of cold lysis buffer (1% Triton X-100, 20 mM Tris (pH = 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethyl-sulfonyl fluoride (PMSF, Sigma), 1X complete EDTA-free Protease Inhibitor cocktail (Roche) and incubation on ice for 10-30 min. After centrifugation (10,000×g for 10 min at 4°C), 10 μl of RQ1 DNase (Promega) was added to the supernatant. IP of FLAG-AGO2 was performed with anti-FLAG M2 mouse antibody (Sigma, F3165) for 3 h at 4°C with rotation. After undergoing five washes with lysis buffer, 10% of the sample beads were subjected to protein extraction and WB by adding LDS sample buffer and DTT and heating the samples at 70°C for 20 min. The remaining 90% of the sample beads were incubated with RQ1 DNase for 30 min for later RNA extraction with TRizol (Invitrogen, USA).

Establishment of an animal model of VM

Six-week-old athymic BALB/c nu/nu male mice (purchased from ProMedican Pharmaceutical Co.) were used to establish the VM model. HUVECs (5×10⁶) stable cell lines which expressing TIE2 protein (WT or L914F mutation) were subcutaneously inoculated into either side of the flank area in an equivalent volume of Matrigel (n = 3 for each group). The lesions were harvested 2 weeks after inoculation and subjected to HE staining. For the miR-18a-5p treatment experiment, HUVECs with the TIE2-L914F mutation were transfected with miR-18a-5p mimic, inhibitor or vehicle for 72 h before subcutaneous injection into mice as previously described (n = 6 per group). The lesion area was measured with Vernier calipers every 3 days, and the final lesions were harvested at 18 days after inoculation. The weight of lesions and the vessel structures were observed after HE staining. All animal experiments were performed in the animal laboratory center of the Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine (Shanghai, China), and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication number 85-23, revised 1996). The study protocol was approved by the Animal Care and Use Committee of the Ninth People’s Hospital (SH9H-2019-A486-1).
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

Supplementary Figure 1. Original, full-length gel and blot images.
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

Supplementary Figure 2. A, C. A heatmap showing the genes differentially expressed between the miR-18-5p changed group and the control group as indicated via RNA-seq is shown. B, D. Volcano plot showing all differentially expressed genes between the miR-18-5p changed group and the control group as indicated via RNA-seq is shown.
Supplementary Figure 3. (A, B) Angiogenesis and migration of HUVECs transfected with NC, NC vector, TSP1 vector, siRNA NC or siTSP1 were evaluated by tube formation (A) and transwell assays (B), respectively. (C-E) Invasion, angiogenesis and migration of HUVECs transfected with NC, miR-18a-5p OE, miR-18a-5p OE + TSP1 vector, miR-18a-5p KD and miR-18a-5p KD + siTSP1 were evaluated by wound healing (C), tube formation (D) and transwell assays (E), respectively.
miR-18a-5p/TSP1/P53 signaling regulates venous malformation
miR-18a-5p/TSP1/P53 signaling regulates venous malformation
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

Supplementary Figure 4. (A) KEGG analysis was used to identify pathway terms enriched in the dysregulated mRNAs in HUVECs with miR-18a-5p KD vs WT. (B, C) GO term enrichment analysis of the biological process (BP), cellular component (CC) and molecular function (MF) categories for the dysregulated mRNAs (B: KD vs WT, C: OE vs WT).
miR-18a-5p/TSP1/P53 signaling regulates venous malformation

**Supplementary Table 1.** Primers of genes used for this study

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cel-miR-39</td>
<td>Forward Primer 5’-CAGAGTCACCG GGTGTAAT-3’&lt;br&gt;Reverse Primer 5’-CCAGTGC GTGTCGGAGTC-3’</td>
</tr>
<tr>
<td>U6</td>
<td>Forward Primer 5’-CTCGGTTCCGCAGACATATACT-3’&lt;br&gt;Reverse Primer 5’-ATTTGCGTATGTCATTGCA-3’</td>
</tr>
<tr>
<td>TSP-1</td>
<td>Forward Primer 5’-GCCATCCGAACACTACATT-3’&lt;br&gt;Reverse Primer 5’-TCGGTTGATAGCAGGAGG-3’</td>
</tr>
<tr>
<td>IGF1</td>
<td>Forward Primer 5’-GCTCTCCAGATGCTACAGCTCC-3’&lt;br&gt;Reverse Primer 5’-GCCCTTCTGAGATCAGCTCC-3’</td>
</tr>
<tr>
<td>NACC1</td>
<td>Forward Primer 5’-CTCTCCGGGCTGAACTTATCA-3’&lt;br&gt;Reverse Primer 5’-AGCGGTTCCGCTAAAAAGA-3’</td>
</tr>
<tr>
<td>LIF</td>
<td>Forward Primer 5’-GCATCAACTCCGAGCTCCCTAG-3’&lt;br&gt;Reverse Primer 5’-CTGAACGCCAGCTACAGCTCC-3’</td>
</tr>
<tr>
<td>CCND2</td>
<td>Forward Primer 5’-ACCTTCCGCGATGCTACAT-3’&lt;br&gt;Reverse Primer 5’-CCCAGGCAAGACCGCTCC-3’</td>
</tr>
<tr>
<td>MMP1</td>
<td>Forward Primer 5’-AAAATTACAGCCAGATTTTGCC-3’&lt;br&gt;Reverse Primer 5’-GGGTGACCTACCCAGAGTGG-3’</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Forward Primer 5’-GGACGGAGATCCCTCATGAAAT-3’&lt;br&gt;Reverse Primer 5’-GGCTGTTGTCTACTACATGG-3’</td>
</tr>
</tbody>
</table>